Esperion Therapeutics Shares Rise

Esperion Therapeutics shares were up almost 20% pre-market Tuesday after the company reported positive top-line results from its phase 2 clinical study evaluating the LDL-C lowering efficacy and safety of the bempedoic acid/ezetimibe combination plus atorvastatin 20 mg, versus placebo, in patients with hypercholesterolemia.

The six-week study met its primary endpoint – 95% of patients receiving treatment achieved greater than or equal to 50% LDL-C lowering reduction, and 90% achieved LDL-C levels of less than 70 mg/dL. “Next year we intend to initiate additional studies to further explore these complementary oral therapies,” said Esperian CEO Tim Mayleben.

Leave A Reply

Your email address will not be published.